On Tuesday, Arvinas Inc (NASDAQ: ARVN) opened lower -5.57% from the last session, before settling in for the closing price of $8.61. Price fluctuations for ARVN have ranged from $7.91 to $42.26 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 87.40% over the past five years. Company’s average yearly earnings per share was noted -39.82% at the time writing. With a float of $59.90 million, this company’s outstanding shares have now reached $68.80 million.
Let’s look at the performance matrix of the company that is accounted for 430 employees. In terms of profitability, gross margin is 98.71%, operating margin of -95.03%, and the pretax margin is -75.32%.
Arvinas Inc (ARVN) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Arvinas Inc is 12.90%, while institutional ownership is 103.52%. The most recent insider transaction that took place on Mar 18 ’25, was worth 74,372. In this transaction Chief Medical Officer of this company sold 8,658 shares at a rate of $8.59, taking the stock ownership to the 110,023 shares. Before that another transaction happened on Mar 18 ’25, when Company’s Officer proposed sale 8,658 for $8.59, making the entire transaction worth $74,372.
Arvinas Inc (ARVN) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -39.82% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -6.83% during the next five years compared to -5.32% drop over the previous five years of trading.
Arvinas Inc (NASDAQ: ARVN) Trading Performance Indicators
Check out the current performance indicators for Arvinas Inc (ARVN). In the past quarter, the stock posted a quick ratio of 4.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.08, a number that is poised to hit -1.00 in the next quarter and is forecasted to reach -4.08 in one year’s time.
Technical Analysis of Arvinas Inc (ARVN)
Arvinas Inc (NASDAQ: ARVN) saw its 5-day average volume 2.39 million, a positive change from its year-to-date volume of 1.78 million. As of the previous 9 days, the stock’s Stochastic %D was 22.56%. Additionally, its Average True Range was 1.22.
During the past 100 days, Arvinas Inc’s (ARVN) raw stochastic average was set at 1.00%, which indicates a significant decrease from 1.96% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 310.20% in the past 14 days, which was higher than the 134.63% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.85, while its 200-day Moving Average is $22.75. Nevertheless, the first resistance level for the watch stands at $8.49 in the near term. At $8.85, the stock is likely to face the second major resistance level. The third major resistance level sits at $9.06. If the price goes on to break the first support level at $7.92, it is likely to go to the next support level at $7.71. Assuming the price breaks the second support level, the third support level stands at $7.35.
Arvinas Inc (NASDAQ: ARVN) Key Stats
There are currently 68,772K shares outstanding in the company with a market cap of 559.12 million. Presently, the company’s annual sales total 263,400 K according to its annual income of -198,900 K. Last quarter, the company’s sales amounted to 59,200 K and its income totaled -45,100 K.
